Market depressed on Cyberonics new market ploy
This article was originally published in Clinica
Shares in Cyberonics, a US device company aimed at managing epilepsy and other neurological disorders through pulsed electrical stimulation of the vagus nerve, fell to a 52-week low following the announcement of its third quarter results and a plan to tap into the market for depression therapy. Industry analysts called the plan "over-aggressive", addressing a market that will not be large enough to compensate the company for the size of investment it is making.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.